Comparative Study Of Nifekalant Versus Amiodarone For Persistent Ventricular Tachycardia/Ventricular Fibrillation

Objective:This study aims to compare the effectiveness and security of nifekalant and amiodarone in patients with persistent ventricular tachycardia or ventricular fibrillation.Methods:Included 84 patients with persistent ventricular tachycardia or ventricular fibrillation admitted into cardiac intensive care unit of TEDA International Cardiovascular Hospital from October 2015 to February 2018.According anti-arrythma drugs which used by patient,we divided patients into nifekalant group and amiodarone group.Observed the efficiency,systolic blood pressure,left ventricular eject fraction,24-hour survival rate,30-day survival rate,adverse reactions,causes of invalid patients' death.SPSS 22.0 software was used to statistically analyze in this study.The t-test was used for the continuous variables that were normally distributed.Otherwise,the non-parametric test was used;the discontinuous variables were chi-square test.Results:1.In comparing the efficacy of nifekalant and amiodarone in the conversion of persistent ventricular tachycardia / ventricular fibrillation,it was found that nifekalant is more effective than amiodarone in reversing persistent ventricular tachycardia / ventricular fibrillation,and The difference was statistically significant(P<0.05).2.Compared with amiodarone,nifekalant can effectively reduce the time for reconstitution of sustained ventricular tachycardia/ventricular fibrillation.Nifekalant can rapidly reverse persistent ventricular tachycardia / ventricular fibrillation significantly(P<0.05).This feature is of great significance in the treatment of persistent ventricular tachycardia / ventricular fibrillation.It can quickly restore hemodynamic disorders and reduce irreversible damage to organ organs due toischemia.3.Comparison of nifekalant and amiodarone in the survival rate of persistent ventricular tachycardia / ventricular fibrillation: nifekalant is effective in improving24-hour survival rate and 1-month survival rate,and 24-hours in the amiodarone group.The difference between survival rate and one-month survival rate was statistically significant(P<0.05).4.In the treatment of persistent ventricular tachycardia / ventricular fibrillation,the adverse reactions of nifekalant and amiodarone were compared: there is no statistically significant difference in the incidence of adverse reactions of nifekalant compared with amiodarone(P>0.05),but the incidence of adverse events in the nifekalant group was smaller than that in the amiodarone group and could be improved after discontinuation.5.During the application of nifekalant / amiodarone,statistical analysis revealed that nifekalant can improve cardiac function(in this study,cardiac function was expressed by left ventricular ejection fraction).Nifekalant had effectively improvement on the left ventricular ejection fraction(P<0.05)and had no significant effect on diastolic blood pressure(P=0.13),systolic blood pressure(P=0.09),and heart rate(P=0.15).6.By comparing the causes of death in patients who had failed to respond to the nifekalant and amiodarone conversions,there was no significant difference in the cause of death between the two patients(P>0.05).Conclusions:The application of nifekalant to treat persistent ventricular tachycardia /ventricular fibrillation is superior to amiodarone in this study,though they showed similar frequency of adverse reactions and all-cause mortality.Nifekalant presents small effects on decreasing blood pressure and heart rate,while has significant effect on improving cardiac function.